Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MOLN
Upturn stock ratingUpturn stock rating

Molecular Partners AG ADR (MOLN)

Upturn stock ratingUpturn stock rating
$3.6
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: MOLN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $10.63

1 Year Target Price $10.63

Analysts Price Target For last 52 week
$10.63 Target price
52w Low $3.36
Current$3.6
52w High $7.6

Analysis of Past Performance

Type Stock
Historic Profit 28.94%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 139.47M USD
Price to earnings Ratio -
1Y Target Price 10.63
Price to earnings Ratio -
1Y Target Price 10.63
Volume (30-day avg) 4
Beta 0.55
52 Weeks Range 3.36 - 7.60
Updated Date 08/29/2025
52 Weeks Range 3.36 - 7.60
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.23

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-25
When -
Estimate -0.4995
Actual -0.5797

Profitability

Profit Margin -
Operating Margin (TTM) -8843.47%

Management Effectiveness

Return on Assets (TTM) -25.53%
Return on Equity (TTM) -49.42%

Valuation

Trailing PE -
Forward PE 1.78
Enterprise Value -1055152
Price to Sales(TTM) 204.8
Enterprise Value -1055152
Price to Sales(TTM) 204.8
Enterprise Value to Revenue 3.81
Enterprise Value to EBITDA 1.23
Shares Outstanding 37392400
Shares Floating 12757150
Shares Outstanding 37392400
Shares Floating 12757150
Percent Insiders -
Percent Institutions 9.73

ai summary icon Upturn AI SWOT

Molecular Partners AG ADR

stock logo

Company Overview

overview logo History and Background

Molecular Partners AG, founded in 2004 in Zurich, Switzerland, is a clinical-stage biopharmaceutical company focused on developing a new class of custom-built protein therapeutics known as DARPins. It has evolved from a research-driven startup to a company with a pipeline of clinical and preclinical programs.

business area logo Core Business Areas

  • DARPin Therapeutics: Development and commercialization of DARPin therapeutics for various diseases, including ophthalmology and oncology.
  • Strategic Partnerships: Collaborations with pharmaceutical companies to develop and commercialize DARPin-based therapeutics.

leadership logo Leadership and Structure

The company is led by a management team with experience in biopharmaceutical development and commercialization. The organizational structure includes research, development, clinical, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • Abicipar (Partnered with AbbVie): A DARPin therapeutic for neovascular age-related macular degeneration (nAMD). While AbbVie discontinued development, the clinical data generated provides value to Molecular Partners. Competitors include Regeneron (Eylea) and Roche/Novartis (Lucentis/Beovu). Market share data is unavailable as it was not commercialized.
  • Ensovibep (Partnered with Novartis): A DARPin therapeutic for COVID-19. Competitors include antivirals from Pfizer (Paxlovid) and Merck (Molnupiravir) and antibody treatments. Ensovibep market share data is not available due to the changing nature of the pandemic response and its authorization status across regions.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. There's increasing demand for novel therapeutics with improved efficacy and safety profiles.

Positioning

Molecular Partners AG ADR is positioned as an innovator in the field of protein therapeutics, leveraging its DARPin technology platform to develop differentiated therapies. Its competitive advantage lies in the unique properties of DARPins, such as high binding affinity and modular design.

Total Addressable Market (TAM)

The TAM varies depending on the specific therapeutic area. The overall global market for biopharmaceuticals is in the hundreds of billions of dollars, and the company targets specific segments within that. Molecular Partners AG ADR is positioned to capture a share of this market with its innovative DARPin therapeutics.

Upturn SWOT Analysis

Strengths

  • Novel DARPin technology platform
  • Strategic partnerships with major pharmaceutical companies
  • Pipeline of clinical and preclinical programs
  • Experienced management team

Weaknesses

  • Reliance on partnerships for commercialization
  • High R&D costs and regulatory hurdles
  • Limited independent commercial infrastructure
  • Clinical trial risks

Opportunities

  • Expanding DARPin technology to new therapeutic areas
  • Developing proprietary DARPin therapeutics
  • Securing regulatory approvals for key products
  • Expanding partnerships to new markets

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Regulatory setbacks
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • RGNX
  • VRTX
  • AMGN

Competitive Landscape

Molecular Partners AG ADR competes with established pharmaceutical companies and other biotechnology firms in the development of novel therapeutics. Its DARPin technology offers a unique competitive advantage, but it faces challenges in commercialization and market access.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by the advancement of its DARPin technology and the establishment of strategic partnerships.

Future Projections: Future growth is contingent on the successful development and commercialization of its DARPin therapeutics. Analyst estimates vary widely depending on clinical trial outcomes and regulatory approvals.

Recent Initiatives: Focus on advancing its clinical pipeline, expanding its DARPin technology platform, and securing new partnerships.

Summary

Molecular Partners AG ADR is a biopharmaceutical company with a novel DARPin technology platform. Its success relies heavily on clinical trial outcomes and strategic partnerships. The company's financial performance is volatile, and it faces competition from larger pharmaceutical companies. Future growth depends on successful pipeline development and commercialization efforts.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Molecular Partners AG ADR Website
  • SEC Filings
  • Analyst Reports

Disclaimers:

This analysis is based on publicly available information and is not financial advice. The information provided is subject to change without notice. Market share estimates are approximate and may not reflect the most current data.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Molecular Partners AG ADR

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-06-16
Co-Founder, CEO, Member of Management Board & Director Dr. Patrick Amstutz Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 153
Full time employees 153

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.